Esperion Q3 total revenue up 69% to $87.3M; net loss $0.16/share

Esperion Therapeutics, Inc.

2025-Q3 EPS reported -$0.43 revenue$234,689,000

U.S. net product revenue $40.7M (+31% YoY); total collaboration revenue $46.7M (+128% YoY).
Net loss $31.3M ($0.16 diluted EPS) vs $29.5M loss ($0.15) in Q3 2024.
Settled with Dr. Reddy's and three other ANDA filers; generic entry blocked until April 2040.
Partner Otsuka received Japan approval and preliminary pricing for NEXLETOL, triggering milestone payments.
Company reiterates 2025 opex guidance of $215-235M; expects sustainable profitability from Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.